AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2025

Feb 7, 2025

32973_dirs_2025-02-07_570218a0-1c20-4cf6-8059-bca1796ae037.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-02-05

Reporting Person: Hall Brett Matthew (CHIEF SCIENTIFIC OFFICER)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-05	Stock Option	$1.91	A	240000	Acquired	2035-02-05	Class A Common Stock (240000)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029.